ClinicalTrials.gg
CompletedNCT02065375Updated Jun 3, 2025Results posted

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

A Phase 2 interventional study of Omaveloxolone Ophthalmic Suspension 1.0% and Omaveloxolone Opthalmic Suspension 0.5% in Inflammation and Pain Following Ocular Surgery, sponsored by Biogen. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-03.

Primary conditionInflammation(the registry's first term)UnverifiedIs this wrong?Inflammation is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by Biogen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study assesses the efficacy and safety of two concentrations of RTA 408 Ophthalmic Suspension in the treatment of patients who have inflammation and pain following ocular surgery.

Read the detailed description

Following ophthalmic surgery, the current standard of care includes a topical ophthalmic corticosteroid or other anti-inflammatory agent to treat ocular inflammation and improve patient comfort. If left untreated, inflammation of the eye may result in further ocular complications including scarring, vision loss, or blindness. Although the exact dosing regimen is physician-dependent, patients are typically prescribed a topical corticosteroid for a period of 2-4 weeks following surgery, being tapered over the course of delivery as the inflammation subsides. Topical anti-inflammatory agents are usually administered multiple times per day, particularly in the early period following ophthalmic surgery. Continuing efforts in drug development aim to identify alternatives to ophthalmic corticosteroid use, due to their well-known local and systemic negative side effects.

02

Conditions studied

  • Inflammation and Pain Following Ocular Surgery

Browse trials for

Keywords

  • RTA 408
  • Ocular surgery
  • Cataract surgery
  • Ocular inflammation
  • Ocular pain
  • Eye inflammation
  • omaveloxolone
03

In context

Inflammation Unverified

3,541 studies on the registry are indexed under Inflammation; 645 are open to participants now.

This study's enrollment of 109 is above the median of 50 across 2,581 interventional studies indexed under Inflammation.

Browse Inflammation studies →

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Compared within Inflammation, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be greater than or equal to 18 years of age of either sex or any race;
  2. Have undergone unilateral cataract extraction via phacoemulsification on the day prior to study enrollment/randomization;
  3. Have a grade of ≥2 in anterior chamber cell score on day after surgery (Day 1);
  4. Have a potential post-operative pin-hole visual acuity (VA) of greater than 1.0 logarithm of the minimum angle of resolution (logMAR) in the operative eye and fellow eye as measured using an Early Treatment for Diabetic Retinopathy Study (ETDRS) chart;

Exclusion criteria

Exclusion Criteria:

  1. Have any intraocular inflammation present in the study eye during the screening slit lamp examination;
  2. Have a score greater than "0" on the Ocular Pain Assessment at Screening in the study eye;
  3. Have an disease or an disease that in the opinion of the Investigator could affect the quality of the ocular surface;
  4. Have active or chronic/recurrent ocular or systemic disease that is uncontrolled and will likely affect wound healing;
  5. Have an intraocular pressure (IOP) ≤ 5 mmHg in either eye;
  6. Require the use of a contact lens or a collagen shield within 72 hours of drug treatment or during the study period in the study eye; be unwilling to discontinue use of contact lenses during study period in the study eye;
  7. Require use of non-diagnostic topical ophthalmic solutions (other than perioperative mydriatics, anesthetics and antiseptics, prophylactic antibiotics, lid scrubs for mild blepharitis, or artificial tears for the management of dry eye) in the study eye for the duration of the study;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    Omaveloxolone Ophthalmic Suspension 1.0%

    Patients will receive a single drop of Omaveloxolone Ophthalmic suspension 1.0% instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery

    Drug: Omaveloxolone Ophthalmic Suspension 1.0%

  • Experimental
    Omaveloxolone Ophthalmic Suspension 0.5%

    Patients will receive a single drop of Omaveloxolone Ophthalmic suspension 0.5% instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery

    Drug: Omaveloxolone Opthalmic Suspension 0.5%

  • Placebo comparator
    Placebo

    Patients will receive a single drop of vehicle for Omaveloxolone Ophthalmic suspension was instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Absence of Anterior Chamber Cells at Day 15 (Visit 5)

    Count of participants who had absence of anterior chamber cells at Day 15. White blood cells were counted. In a healthy eye, the anterior chamber should not have any blood cells present. "Yes" indicates an absence of anterior chamber cells. Data for visits after a patient was discontinued for lack of efficacy were imputed as failures and missing data were imputed using last observation carried forward.

    Time frame: 15 days after the participant receives the first dose

  2. Absence of Ocular Pain at Day 4 (Visit 3)

    Participants were asked to report their pain on Day 4 using the Numerical Pain Rating Scale (NPRS) for patients receiving active drug compared to patients receiving placebo. The NPRS is an 11-point numeric scale, which ranges from "0" representing "no pain" to "10" representing the "worst pain imaginable". Lower scores indicate less pain. Participants reporting '0' were recorded as "Yes" while patients reporting any other pain score were recorded as "No". Data for visits after a patient was discontinued for lack of efficacy were imputed as failures and missing data were imputed using last observation carried forward.

    Time frame: 4 days after the participant receives the first dose

07

Results

Posted Apr 19, 2023

Participant flow

Participant flow — Overall Study
MilestoneOmaveloxolone Ophthalmic Suspension 1.0%Omaveloxolone Ophthalmic Suspension 0.5%Placebo
Started373339
Completed treatment191525
Completed373339
Not completed000

Outcome measures

PrimaryAbsence of Anterior Chamber Cells at Day 15 (Visit 5)

Count of participants who had absence of anterior chamber cells at Day 15. White blood cells were counted. In a healthy eye, the anterior chamber should not have any blood cells present. "Yes" indicates an absence of anterior chamber cells. Data for visits after a patient was discontinued for lack of efficacy were imputed as failures and missing data were imputed using last observation carried forward.

Time frame:
15 days after the participant receives the first dose
Reported as:
Count of participants · Participants
Absence of Anterior Chamber Cells at Day 15 (Visit 5)
ParticipantsOmaveloxolone Ophthalmic Suspension 1.0%Omaveloxolone Ophthalmic Suspension 0.5%Placebo
Yes101211
No272128
Statistical analysis
  • Omaveloxolone Ophthalmic Suspension 1.0% vs Placebo · Chi-squared · p = 0.4543 · Difference in proportion of patients: -1.2 · 95% CI -21.3 to 18.9p values from Pearson chi-squared statistical test between the Omaveloxolone Ophthalmic suspension 1.0% and placebo were one sided.
  • Omaveloxolone Ophthalmic Suspension 0.5% vs Placebo · Chi-squared · p = 0.2297 · Difference in proportion of patients: 8.2 · 95% CI -13.5 to 29.8p values from Pearson chi-squared statistical test between the Omaveloxolone Ophthalmic suspension 0.5% and placebo were one sided.
PrimaryAbsence of Ocular Pain at Day 4 (Visit 3)

Participants were asked to report their pain on Day 4 using the Numerical Pain Rating Scale (NPRS) for patients receiving active drug compared to patients receiving placebo. The NPRS is an 11-point numeric scale, which ranges from "0" representing "no pain" to "10" representing the "worst pain imaginable". Lower scores indicate less pain. Participants reporting '0' were recorded as "Yes" while patients reporting any other pain score were recorded as "No". Data for visits after a patient was discontinued for lack of efficacy were imputed as failures and missing data were imputed using last observation carried forward.

Time frame:
4 days after the participant receives the first dose
Reported as:
Count of participants · Participants
Absence of Ocular Pain at Day 4 (Visit 3)
ParticipantsOmaveloxolone Ophthalmic Suspension 1.0%Omaveloxolone Ophthalmic Suspension 0.5%Placebo
Yes11920
No262419
Statistical analysis
  • Omaveloxolone Ophthalmic Suspension 1.0% vs Placebo · Chi-squared · p = .0280 · Difference in proportion of patients: -21.6 · 95% CI -43.1 to 0.00p values from Pearson chi-squared statistical test between the Omaveloxolone Ophthalmic suspension 1.0% and placebo were one sided.
  • Omaveloxolone Ophthalmic Suspension 0.5% vs Placebo · Chi-squared · p = 0.0192 · Difference in proportion of patients: -24.0 · 95% CI -45.8 to -2.2p values from Pearson chi-squared statistical test between the Omaveloxolone Ophthalmic suspension 0.5% and placebo were one sided.

Adverse events

Collected over From Day 1 (24 +/- 6 hours after surgery) to Day 21. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Omaveloxolone Ophthalmic Suspension 1.0%: Study Eye0/37 (0%)0/37 (0%)18/37 (48.6%)
Omaveloxolone Ophthalmic Suspension 1.0%: Non-study Eye0/37 (0%)0/37 (0%)0/37 (0%)
Omaveloxolone Ophthalmic Suspension 0.5%: Study Eye0/33 (0%)0/33 (0%)15/33 (45.5%)
Omaveloxolone Ophthalmic Suspension 0.5%: Non-study Eye0/33 (0%)0/33 (0%)2/33 (6.1%)
Placebo: Study Eye0/39 (0%)0/39 (0%)13/39 (33.3%)
Placebo: Non-study Eye0/39 (0%)0/39 (0%)1/39 (2.6%)
Omaveloxolone Ophthalmic Suspension 1.0%: Non-ocular AE0/37 (0%)0/37 (0%)2/37 (5.4%)
Omaveloxolone Ophthalmic Suspension 0.5%: Non-ocular AE0/33 (0%)0/33 (0%)2/33 (6.1%)
Placebo: Non-ocular AE0/39 (0%)0/39 (0%)1/39 (2.6%)
Most frequent other events
Showing 10 of 28
Most frequent other events
EventOmaveloxolone Ophthalmic Suspension 1.0%: Study EyeOmaveloxolone Ophthalmic Suspension 1.0%: Non-study EyeOmaveloxolone Ophthalmic Suspension 0.5%: Study EyeOmaveloxolone Ophthalmic Suspension 0.5%: Non-study EyePlacebo: Study EyePlacebo: Non-study EyeOmaveloxolone Ophthalmic Suspension 1.0%: Non-ocular AEOmaveloxolone Ophthalmic Suspension 0.5%: Non-ocular AEPlacebo: Non-ocular AE
Conjunctival hyperaemiaEye disorders11/370/379/330/337/390/390/370/330/39
Corneal oedemaEye disorders3/370/375/330/331/390/390/370/330/39
Corneal disorderEye disorders4/370/371/330/330/390/390/370/330/39
Eye painEye disorders4/370/371/330/331/390/390/370/330/39
PhotophobiaEye disorders2/370/373/330/334/390/390/370/330/39
Corneal striaeEye disorders2/370/373/330/333/390/390/370/330/39
Visual acuity reducedEye disorders2/370/373/331/331/390/390/370/330/39
Eye irritationEye disorders2/370/372/330/330/390/390/370/330/39
HeadacheNervous system disorders0/370/370/330/330/390/391/372/330/39
Corneal depositsEye disorders2/370/370/330/330/390/390/370/330/39

Baseline characteristics

Intent-to-treat population (all randomized patients with available data)

Age, Continuous
Age, Continuous(years)Omaveloxolone Ophthalmic Suspension 1.0%Omaveloxolone Ophthalmic Suspension 0.5%PlaceboTotal
Mean67.9 ± 9.768.1 ± 9.3168.9 ± 9.4768.3 ± 9.42
Sex: Female, Male
Sex: Female, Male(Participants)Omaveloxolone Ophthalmic Suspension 1.0%Omaveloxolone Ophthalmic Suspension 0.5%PlaceboTotal
Female23182061
Male14151948
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Omaveloxolone Ophthalmic Suspension 1.0%Omaveloxolone Ophthalmic Suspension 0.5%PlaceboTotal
Hispanic or Latino65213
Not Hispanic or Latino30283795
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Omaveloxolone Ophthalmic Suspension 1.0%Omaveloxolone Ophthalmic Suspension 0.5%PlaceboTotal
American Indian or Alaska Native0101
Asian3227
Native Hawaiian or Other Pacific Islander0000
Black or African American66315
White27243485
More than one race0000
Unknown or Not Reported1001
Region of Enrollment
Region of Enrollment(participants)Omaveloxolone Ophthalmic Suspension 1.0%Omaveloxolone Ophthalmic Suspension 0.5%PlaceboTotal
United States373339109
08

Study locations

6 sites
  • Garden Grove, California 92843, United States
  • Fort Myers, Florida 33907, United States
  • Kansas City, Missouri 64133, United States
  • Elizabeth City, North Carolina 27909, United States
  • Austin, Texas 78731, United States
  • Houston, Texas 75022, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Sep 2014, 7 months.

Results were first posted in Apr 2023, 8 years 6 months after primary completion. A results delay was requested in Oct 2014.

Of 36 industry-sponsored phase 2 interventional studies under Inflammation, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.

Counting every sponsor, half of 149 studies reached it within 29 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2014
First posted
Feb 19, 2014
StartActual
Feb 28, 2014
Primary completionActual
Sep 30, 2014
CompletionActual
Sep 30, 2014
Results delay requested
Oct 22, 2014
Results first posted
Apr 19, 2023
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02065375
Lead sponsor
Biogen
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Feb 19, 2014
Start date
Feb 28, 2014
Primary completion
Sep 30, 2014
Completion
Sep 30, 2014
Results posted
Apr 19, 2023
Last update
Jun 3, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omaveloxolone

Start the discussion